AI Designs Novel Antibodies For Hard Targets
Researchers and biotech companies are using generative AI to create novel antibody therapeutics, advancing from lab validation to early clinical studies since last year. Generate:Biomedicines reported promising late-September results and launched a Phase 3 trial involving roughly 1,600 severe asthma patients, while Baker lab’s RFdiffusion and other models produced AI-designed nanobodies and antibodies that bind targets in lab tests. These developments could shorten discovery timelines and reach previously undruggable targets, though safety and immune responses remain to be validated.
Scoring Rationale
High novelty and industry-wide implications from validated models and trials, tempered by limited peer-reviewed evidence and remaining safety uncertainties.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
